Benefits
LDL cholesterol reductions reported by Cuban trials
Trials run mostly by one research institute reported lower LDL cholesterol at 5 to 40 mg a day; in one large Havana trial, 5 and 10 mg a day lowered it by about 18% and 26%. A pooled analysis of 22 trials found lower LDL overall, but the effect was larger in Cuban studies than elsewhere and did not rise with dose, and its authors called for more trials to confirm it.
Independent cholesterol trials did not replicate the Cuban results
When groups in Germany and Canada tested sugarcane policosanol, including the original Cuban material, LDL cholesterol fell no more than on placebo, even at 80 mg a day, and a US trial of 20 mg a day also found no change. A pooled comparison of 131 trials covering ten cholesterol-focused nutraceuticals found policosanol was the only one that did not lower LDL cholesterol.
Blood pressure results from the Havana institute and a supplier-linked group
A pooled analysis of nineteen trials found systolic pressure about 3 mmHg lower, with wide variation between studies. One Havana trial of 20 mg a day, reported as two 200-patient strata, found lower systolic and diastolic pressure than placebo at 12 weeks. Korean and Japanese trials led by one investigator, now at a supplier's research institute, found lower systolic pressure than placebo at 20 mg a day.
HDL cholesterol rise reported in supplier-linked research
In a 12-week Japanese trial of 20 mg a day, HDL cholesterol ended about 9.5% higher than placebo, but only in the 15 policosanol and 17 placebo participants left after low-compliance participants were excluded, and LDL, total cholesterol and triglycerides did not differ. The lead author is based at the Raydel Research Institute, and the tablets were Raydel's product. The German, Canadian and US trials saw no HDL change.
Mechanism of action
A blend of very long chain plant alcohols
Policosanol is a mixture of primary alcohols 24 to 34 carbons long, refined from sugarcane wax. Octacosanol makes up about 60 to 70 percent of the Cuban specification, with triacontanol, hexacosanol and dotriacontanol as smaller parts. Other supplements may use different waxes and ratios.
Proposed brake on liver cholesterol synthesis
In rat liver cancer cells, policosanol cut cholesterol synthesis by up to about 30 percent without inhibiting HMG-CoA reductase directly; it activated AMP-kinase, which switches the enzyme down. Triacontanol, not octacosanol, reproduced the effect. This is cell work and has not been shown in people at supplement doses.
The authentic-product argument
Failed replications outside Cuba were often explained away as using non-Cuban mixtures. A Canadian crossover trial tested authentic Cuban sugarcane policosanol at 10 mg a day, and the German trial used Cuban sugarcane-derived material at up to 80 mg; in neither did blood lipids differ from placebo, so product source alone does not explain why the original results have not been reproduced.
HDL quality hypothesis
A Korean and Japanese research program proposes that policosanol makes HDL particles more antioxidant and less prone to glycation, and reports less oxidized LDL and VLDL. These measures are laboratory assays on trial blood samples and zebrafish, and they come largely from one supplier-linked research group.
Clinical trials
Randomized, double-blind, placebo-controlled trial of policosanol 5 mg/day for 12 weeks and then 10 mg/day for 12 weeks, from the Center of Natural Products at Havana's National Center for Scientific Research. (Más et al. 1999, Clin Pharmacol Ther)
437 patients with type II hypercholesterolemia and additional coronary risk factors, after 5 weeks on a standard lipid-lowering diet.
LDL cholesterol fell 18.2% on 5 mg and 25.6% on 10 mg, total cholesterol fell 13.0% and 17.4%, and HDL cholesterol rose 15.5% and 28.4%. The placebo group had 11 serious adverse events, 7 of them vascular, against none on policosanol; the trial was not designed to test events. Independent trials using Cuban material later found no lipid change.
Multicenter randomized, double-blind, placebo-controlled trial of Cuban sugarcane-derived policosanol at 10, 20, 40 or 80 mg/day for 12 weeks after a 6-week placebo and diet run-in. (Berthold et al. 2006, JAMA)
143 patients in Germany with hypercholesterolemia or combined hyperlipidemia and LDL cholesterol of at least 150 mg/dL, after a 6-week placebo and diet run-in.
LDL cholesterol fell by no more than 10% from baseline in any group, no dose differed significantly from placebo, and there was no dose-response. Total, HDL and VLDL cholesterol, triglycerides, lipoprotein(a) and cholesterol ratios were also unchanged. There were no serious adverse events. The authors concluded that usual and high doses do not lower lipids beyond placebo.
Randomized, double-blind, placebo-controlled crossover trial of 10 mg/day Cuban sugarcane policosanol given in margarine under supervision for 28 days, McGill University. (Kassis et al. 2006, Am J Clin Nutr)
21 otherwise healthy hypercholesterolemic volunteers, studied by a McGill University group in Canada.
Plasma total, LDL and HDL cholesterol and triglycerides did not differ between policosanol and placebo, and body weight was stable. Because the trial used authentic Cuban material, it undercuts the argument that earlier failed replications simply used the wrong product. It was small and short.
Meta-analysis of randomized controlled trials of sugarcane policosanol in dyslipidemia, searching 11 databases. (Gong et al. 2018, Mol Nutr Food Res)
22 studies with 1,886 participants, from Cuba and other countries.
Pooled results favored policosanol for total and LDL cholesterol and for raising HDL cholesterol, while triglycerides and body weight were unchanged. Heterogeneity was high, Cuban studies showed larger effects than studies from elsewhere, and the effect was not proportional to dose, so the authors said more trials are needed to confirm efficacy.
Random-effects network meta-analysis of randomized trials of ten nutraceuticals marketed for LDL lowering, searched to February 2021. (Osadnik et al. 2022, Pharmacol Res)
131 trials with 13,062 adults testing artichoke, berberine, bergamot, garlic, green tea extract, plant sterols and stanols, policosanols, red yeast rice, silymarin or spirulina.
Every nutraceutical except policosanols lowered LDL and total cholesterol more than placebo or no intervention, with bergamot and red yeast rice ranking highest. The authors concluded that policosanols have no effect on the lipid profile.
Randomized, parallel, double-blind, double-dummy, placebo-controlled 12-week trial at Mount Sinai Medical Center, Miami Beach, with four arms: policosanol 20 mg, atorvastatin 10 mg, both, or placebo. (Cubeddu et al. 2006, Am Heart J)
99 adults with LDL cholesterol of 140 to 189 mg/dL.
Policosanol did not change total, LDL or HDL cholesterol or triglycerides compared with baseline or placebo, and adding it to atorvastatin gave no further lowering. Liver enzyme and creatine phosphokinase levels were not affected. The authors proposed listing policosanol among supplements lacking scientific support.
Randomized, placebo-controlled, double-blind crossover trial of a policosanol supplement (Octa-60) for 12 weeks per period with a 4-week washout, North-West University. (Greyling et al. 2006, Br J Nutr)
19 adults with high cholesterol, including some with the inherited (heterozygous familial) form, who completed both periods.
Total and LDL cholesterol did not differ between policosanol and placebo. Small drops from baseline in one subgroup matched the placebo changes. The authors suggested the product's alcohol composition might differ from the products used in earlier trials.
Randomized, double-blind, placebo-controlled multicenter trial, 12 weeks, analyzed by intention to treat; funded by Havana's National Center for Scientific Research, the institute behind the original Cuban lipid trials, whose clinical trials unit staff are coauthors; tablets made by Laboratorios MedSol, Havana; the authors declared no conflicts. (Revueltas Aguero et al. 2025, J Clin Hypertens (Greenwich))
200 Cuban adults aged 20 to 60 with grade I high blood pressure (systolic 140 to 159 mmHg and diastolic 90 to 99 mmHg), 100 per group; one stratum of a 400-patient trial.
The authors report systolic pressure fell by more than 10 mmHg versus baseline and placebo (p < 0.001), the primary outcome, and diastolic pressure also fell versus placebo. 74% on policosanol versus 12% on placebo reached a 10 mmHg systolic drop from baseline. The authors also report lower LDL and higher HDL cholesterol.
Randomized, placebo-controlled, double-blind trial of Raydel policosanol tablets (Cuban sugarcane policosanol, obtained from Raydel Japan); lead author at the Raydel Research Institute; the paper states no external funding. (Cho et al. 2023, Int J Mol Sci)
72 healthy Japanese adults with LDL cholesterol 120 to 159 mg/dL were enrolled; 30 policosanol and 35 placebo were analyzed for blood pressure, and 15 and 17 for lipids after low-compliance exclusions.
At week 12 systolic pressure was 106.1 versus 112.7 mmHg (between-group p = 0.026); diastolic pressure did not differ (p = 0.195). In the per-protocol subset, HDL cholesterol was 9.5% higher than placebo, while LDL, total cholesterol and triglycerides did not differ over time between groups.
Randomized, double-blind, placebo-controlled trial at Yeungnam University; policosanol raw material from Rainbow & Nature Pty Ltd (Thornleigh, Australia), tablets made by CosmaxBio; funded by Korean government grants; the authors declared no conflict of interest; the senior author, Cho KH, later led the Raydel-affiliated Japanese trial. (Park et al. 2019, Int J Environ Res Public Health)
84 healthy Korean adults with prehypertension (average systolic about 136 mmHg) randomized to placebo, 10 mg or 20 mg a day; 76 completed.
In between-group analysis, 20 mg lowered systolic pressure at 12 weeks (p = 0.020) and diastolic pressure at 8 and 12 weeks (p = 0.041 and 0.035) versus placebo. Both doses lowered total and LDL cholesterol versus placebo (LDL down 21% and 18%), a lipid result that the independent trials did not reproduce.